Skip to main content
SpringerLink
Log in

Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines

  • Original Article
  • Published:
Archives of Virology Aims and scope Submit manuscript

Abstract

The addition of 0.5% of a chitosan derivative to inactivated influenza vaccines injected parenterally resulted in a four or six to tenfold increase in antibody titres after a single-dose or two-dose intramuscular immunization of mice, respectively, in comparison with antibody titres after immunization without chitosan. Chitosan-adjuvanted vaccines enhanced antibody titers against drift variants of A- and B-type human influenza viruses four to six times compared with the vaccines without chitosan. Inactivated avian influenza virus A/H5N2 admixed with chitosan, when administered to mice challenged afterwards with the same virus, showed higher immunogenicity and protective efficacy compared with the antigen without chitosan.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Belshe RB, Gruber WC, Mendelman PM, Cho I, Reisinger K, Block SL, Wittes J, Iacusio D, Piedra P, Treanor J, King I, Kotloff K, Bernstein DI, Hayden FG, Zangwill K, Yan L, Wollf M (2000) Efficacy of vaccination with live attenuated, cold adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 136:168–175

    Article  PubMed  CAS  Google Scholar 

  2. Couch R (2000) Influenza: prospects for control. Ann Intern Med 133:992–998

    PubMed  CAS  Google Scholar 

  3. De Jong J, Beyer W, Palache A, Rimmelzwaan G, Osterhaus A (2000) Mismatch between the 1997/1998 influenza vaccine and the major epidemic A/H3N2 virus strain as the cause of an inadequate vaccine-induce antibody response to this strain in the elderly. J Med Virol 61:94–99

    Article  PubMed  Google Scholar 

  4. Felt O, Buri P, Curny R (1998) Chitosan, a unique polysaccharide for drug delivery. Drug Dev Ind Pharm 24:979–993

    PubMed  CAS  Google Scholar 

  5. Gluck U, Gebbers J, Gluck R (1999) Phase 1 evaluation intranasal virosomal influenza vaccine with and without E. coli heat-labile toxin in adult volunteers. J Virol 73:7780–7786

    PubMed  CAS  Google Scholar 

  6. Gross P, Hermogenes A, Sacks H, Lau J, Lewandowski R (1995) The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med 123:518–527

    PubMed  CAS  Google Scholar 

  7. Hehme N, Engelman H, Kuenzel W, Neumeier E, Saenger R (2004) Immunogenicity of a monovalent aluminium-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 103:163–171

    Article  PubMed  CAS  Google Scholar 

  8. Hirano S (1996) Chitin biotechnology application. Biotechnol Ann Rev 2:237–258

    Article  CAS  Google Scholar 

  9. Illum L, Jabbal-Gill I, Hincheliffe A, Fisher A, Davis S (2001) Chitosan as a novel nasal delivery system for vaccines. Drug Deliv 51:81–96

    Article  CAS  Google Scholar 

  10. Kendal A, Pereira M, Skehel J (1982) Concepts and procedures for laboratory-based influenza surveillance. WHO, Geneva

    Google Scholar 

  11. Mendelman PM, Rappaport R, Cho I, Block S, Gruber W, August M, Dawson D, Cordova J, Kemble G, Mahmood K, Palladino G, Lee MS, Razmpour A, Stoddard J, Forrest BF (2004) Live attenuated influenza vaccine induces cross-reactive antibody responses in children against an a/Fujian/411/2002-like H3N2 antigenic variant strain. Pediatr Infect Dis 23:1053–1055

    Article  Google Scholar 

  12. Mutsch M, Zhou W, Rhodes P, Bopp M, Chen RT, Linder T, Spyr C, Steffen R (2004) Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. New Engl J Med 350:896–903

    Article  PubMed  CAS  Google Scholar 

  13. Nicholson K, Tyrrel D, Harrison P, Plotter C, Jennings R, Clark A, Shild G, Wood J, Yetts R, Seagroat V, Huggins A, Anderson S (1979) Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactions. J Biol Stand 7:123–136

    Article  PubMed  CAS  Google Scholar 

  14. Palache A (1997) Influenza vaccines: a reappraisal of their use. Drugs 54:841–856

    Article  PubMed  CAS  Google Scholar 

  15. Palache A (2006) International meetings on pandemic preparedness and control. Infl Bull ESWI 21:6–7

    Google Scholar 

  16. Podda A (2001) The adjuvanted influenza vaccine with novel adjuvants: experience with the MF 59-adjuvanted vaccine. Vaccine 19:2637–2680

    Article  Google Scholar 

  17. Podda A, Del Guidice G (2003) MF 59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2:197–204

    Article  PubMed  CAS  Google Scholar 

  18. Potter C (1982) Inactivated influenza vaccine. In: Bear A (ed) Basic and applied influenza research. CRC Press, Boca Raton, pp 116–158

    Google Scholar 

  19. Smirnov Y, Lipatov A, van Beek R, Gitelman A, Osterhaus A, Claas E (2000) Characterization of a adaptation of an avian influenza A (H5N2) virus to a mammalian host. Acta Virol 41:1–8

    CAS  Google Scholar 

  20. Wood J, Williams M (1998) History of inactivated influenza vaccines. In: Nicholson K, Webster R, Hay A (eds) Textbook of influenza. Blackwell, London, pp 317–323

    Google Scholar 

Download references

Acknowledgments

The authors are deeply grateful to Dr. Smirnov, who kindly provided us with the mouse-adapted avian influenza virus A/H5N2 strain that was needed for our investigations.

Author information

Authors and Affiliations

  1. Mechnikov Research Institute for Vaccines and Sera, 1-st Dubrovskaja str., 15, 115088, Moscow, Russia

    Y. Ghendon, S. Markushin, G. Krivtsov & I. Akopova

Authors
  1. Y. Ghendon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Markushin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Krivtsov
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. Akopova
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y. Ghendon.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ghendon, Y., Markushin, S., Krivtsov, G. et al. Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines. Arch Virol 153, 831–837 (2008). https://doi.org/10.1007/s00705-008-0047-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00705-008-0047-4

Keywords

Search

Navigation